This study looks at whether a combination of drugs works better than the standard treatment for people with a specific type of colon cancer that has spread, known as metastatic colorectal cancer (mCRC). The cancer has a special mutation called KRAS p.G12C. Researchers will test if drugs like sotorasib and panitumumab combined with a treatment called FOLFIRI (a mix of chemotherapy drugs) fight the cancer better than FOLFIRI alone, with or without another drug called bevacizumab-awwb.

Participants must have not received any prior treatment for their cancer. They need to have the KRAS mutation confirmed and must be in good health overall, with their organs working well. Those with untreated brain cancer or certain lung conditions cannot join.

• The study compares different treatments to see which keeps cancer from growing longer.
• Participants must have a specific gene mutation and be in good general health.
• Some health conditions might prevent joining the study.